Welcome Visitor
Today is Tuesday, January 17, 2017

Tennessee settles with GlaxoSmithKline over diabetes drug

Comment   Email   Print
Related Articles

Tennessee's attorney general and 37 states reached a $90 million agreement with GlaxoSmithKline LLC to resolve allegations that the pharmaceutical company unlawfully promoted its diabetes drug, Avandia.

As a result, Tennessee will receive $3 million of this multistate consumer protection investigation.

The attorneys general alleged GlaxoSmithKline engaged in unfair and deceptive practices by misrepresenting Avandia’s cardiovascular risks and safety profile.

“We appreciate the cooperative work of all the states participating in this investigation,” Attorney General Bob Cooper said. “We remain vigilant in our efforts to stop marketing practices by some drug companies that may risk the health of Tennesseans.”

As part of the agreement, GlaxoSmithKline agreed to reform how it markets and promotes diabetes drugs.

Going forward, it may not:

• Make any false, misleading or deceptive claims about any diabetes drug;

• Make comparative safety claims not supported by substantial evidence or substantial clinical experience;

• Present favorable information previously thought of as valid but rendered invalid by contrary and more credible recent information;

• Promote investigational drugs; or

• Misuse statistics or otherwise misrepresent the nature, applicability, or significance of clinical trials.

The agreement also has the following terms that are effective for at least eight years:

• Summaries must be posted of all sponsored observational studies or meta-analyses conducted by the company that are designed to inform the effective, safe, and appropriate use of of its diabetes drugs;

• The company shall post summaries of sponsored clinical trials of diabetes products within eight months of the primary completion date;

• It shall register and post all company-sponsored clinical trials as required by federal law; and

• It shall comply with industry requirements for papers submitted to biomedical journals for publication.

Consumers may file complaints regarding prescription drug advertisements or any other deceptive conduct by going online to www.tn.gov/consumer or calling the TDCI Division of Consumer Affairs at 615-741-4737 or toll-free in Tennessee at 1-800-342-8385.

Read more from:
Advertising, Attorney General, Avandia, Bob Cooper, Court, Diabetes, District Court, GlaxoSmithKline, Health Care, Medicine, Tennessee
Comment   Email   Print
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: